To date 19 posters have been submitted. Full abstracts can be viewed and downloaded using this link

 

1. Determination of ghb in dried blood spots using a simple gc-ms method
2. Assessment of analyte losses in a human dried blood spot assay for the determination of indapamide.
3. Dried blood spot sampling in combination with lc-ms/ms for quantitative analysis of new chemical entities
4. Determination of lumefantrine after capillary sampling onto filter paper
5. Dried blood spotting – astrazeneca evaluation
6. LC-MS/MS analysis of immunosuppressants in whole blood: comparison of dried blood spots, heat shock or cryogenically treated blood and denatured blood
7. Application of dried blood spot pk/tk sampling in drug development
8. On-line dbs process for clinical and pharmaceutical approaches
9. The simultaneous analysis of everlolimus, tacrolimus and cyclosporin-a in dried blood spots using lc-msms
10. Dried blood spot (dbs) analysis of cyclosporin a in whole blood by uplc-ms/ms.
11. Application and validation of the dried blood spot technique for the determination of quetiapine, norquetiapine and quetiapine sulphoxide in human whole blood
12. Comparative analysis of buprenorphine and oxycodone in human dried blood spots (dbs) using lc-ms/ms
13. The effect of hematocrit on assay bias when using dried blood spots samples for the quantitative bioanalysis of drugs
14. Investigating the effects of anticoagulant type and spotting technique on the dried blood spot analysis of sitamquine by hplc-ms/ms
15. Card technologies - the future
16. Development and validation of a high sensitivity method for the determination of tacrolimus (fk506) using dried blood spot technique in human whole blood by lc-ms/ms.
17. Development of analytical methods for the determination and quantification of antiepileptic drugs in dried blood spots
18. On-line desorption of dried blood spots coupled to hydrophilic interaction/reversed-phase lc/ms/ms system for the simultaneous analysis of pharmaceuticals and their polar metabolites
19. Feasibility of dbs implementation in bioanalysis of biopharmaceuticals; kineret, a case study